Europe PMCopen access
Mosunetuzumab: A bispecific CD20 × CD3 antibody for follicular lymphoma with promising evidence in other B-NHL subtypes
Bispecific antibody, Immunotherapy, CD20, CD3, Follicular Lymphoma, B-cell Malignancies
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 651918
Conceptio Open Knowledge Archive — every document is proof-bundled with source, license, and retrieval metadata.